Cisplatin and irinotecan in upper gastrointestinal malignancies

ONCOLOGY

Volumn 15, Issue 3 SUPPL. 5, 2001, Pages 42-45

  O'Reilly, Eileen M ^a   Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; IRINOTECAN;

DRUG COMBINATION; GASTROINTESTINAL TUMOR; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CISPLATIN; DRUG THERAPY, COMBINATION; GASTROINTESTINAL NEOPLASMS; HUMAN;

EID: 0035292514     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2001. CA Cancer J din 51:15-36, 2001.
2. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for the Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group [see comments]. J Clin Oncol 18:2648-2657, 2000.
3. Bokemeyer C, Hartmann JT, Lampe CS, et al: Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 24:S19-96-S19-100, 1997.
4. Kim YH, Shin SW, Kim BS, et al: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85:295-301, 1999.
5. Kollmannsberger C, Quietzsch D, Haag C, et al: A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458-462, 2000.
6. Barone C, Cassano A, Landriscina M, et al: Bolus and infusional 5-fluorouracil combined with cisplatin in advanced gastric cancer [In Process Citation]. Oncol Rep 7:1305-1309, 2000.
7. Hsiang YH, Wu HY, Liu LF: Topoisomerases: Novel therapeutic targets in cancer chemotherapy. Biochem Pharmacol 37:1801-1802, 1988.
8. Lavelle F, Bissery MC, Andre S, et al: Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 23:11-20, 1996.
9. Rothenberg ML: CPT-11: An original spectrum of clinical activity. Semin Oncol 23:21-26, 1996.
10. Kelsen DP: Neoadjuvant therapy of squamous cell carcinoma of the esophagus. Recent Results Cancer Res 155:105-112, 2000.
11. Ajani JA: Current status of therapy for advanced gastric carcinoma. Oncology 12:99-102, 1998.